310 related articles for article (PubMed ID: 21621325)
1. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
5. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
[TBL] [Abstract][Full Text] [Related]
6. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
7. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
8. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS
Cancer Res; 2000 Aug; 60(15):4093-7. PubMed ID: 10945615
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
10. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
13. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Yeh IT; Reddick RL; Kumar AP
Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
[TBL] [Abstract][Full Text] [Related]
14. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
[TBL] [Abstract][Full Text] [Related]
15. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).
Mentor-Marcel R; Lamartiniere CA; Eltoum IE; Greenberg NM; Elgavish A
Cancer Res; 2001 Sep; 61(18):6777-82. PubMed ID: 11559550
[TBL] [Abstract][Full Text] [Related]
16. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
[TBL] [Abstract][Full Text] [Related]
17. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice.
Fritz WA; Lin TM; Cardiff RD; Peterson RE
Carcinogenesis; 2007 Feb; 28(2):497-505. PubMed ID: 17052998
[TBL] [Abstract][Full Text] [Related]
18. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade.
Li H; Gerald WL; Benezra R
Cancer Res; 2004 Sep; 64(17):6137-43. PubMed ID: 15342397
[TBL] [Abstract][Full Text] [Related]
19. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 accelerates multistep prostate carcinogenesis in vivo.
Bruckheimer EM; Brisbay S; Johnson DJ; Gingrich JR; Greenberg N; McDonnell TJ
Oncogene; 2000 Nov; 19(46):5251-8. PubMed ID: 11077442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
